港股異動 | 康龍化成(3759.HK)漲4.8% 收購Recipharm旗下原料藥生產基地
格隆匯1月10日丨康龍化成(3759.HK)股價持續拉昇,現報111.2港元,漲幅4.8%;公司A股漲1.3%,報127.2元。1月10日,康龍化成(北京)新藥技術股份有限公司宣佈成功收購Recipharm旗下位於英國Cramlington的Aesica藥業。Cramlington生產基地位於英國紐卡斯爾,擁有超過100立方米反應釜的生產能力,可提供從中試至噸級商業化規模的cGMP原料藥生產服務。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.